C4 Therapeutics Inc részvény ár

C4 Therapeutics Inc is a biopharmaceutical company specialising in methodology for the treatment of cancer, neurodegenerative conditions and other diseases through the development of new therapeutic products. They are based on the use of the natural regulation of protein levels in the body for the targeted destruction of those that cause disease.

CCCC.O's approach is to use proteolysis technology (the process of cleaving one or more peptide bonds in a protein molecule using enzymes). Simply put, it allows to calculate disease-causing proteins and destroy them. To date, there are several developments at the stage of preclinical trials. Two programs will enter the first clinical phase at the end of 2021, the other two at the end of 2022.

C4 Therapeutics Inc went public in October 2020 and has been in the focus of traders' ever since.

Traders deservedly consider this stock one of the most visible on the market due to its volatility and unpredictability. Beginners will find it quite difficult to keep up with the stock price of C4 Therapeutics Inc. However, if you understand the general correlations and monitor how the chart reacts to certain news, you may be able to make effective trades. You can buy and also sell this asset as a CFD, speculating on the price changes.

You can see Bid and Ask online prices in real-time on this page. However, the most accurate quotes are waiting for you in trading terminals.

Please note that in the case companies issue a dividend, the ex-dividend date, that is the date without entitlement to the dividend, is known in advance and is displayed in the corresponding calendar on our website. If you have a Buy position open on the ex-dividend date, your trading account will be credited with the dividend net of any withholding taxes. In the case of holding a Sell position, the whole dividend will be debited to your account. If you have questions about this, our customer support team are on hand to assist.

Start Trading on CCCC.O CFD Stocks with FxPro Today!